Although many more questions remain to be answered, including how immunogenic cancer cell death contributes to treatment effect; how T cells are activated; and how DCs cross-talks with tumor cell and T cells, the precision medicine we put forward in current work for KRAS mutation positive/ZNF24-low lung cancer patients warrant further study. Here, ZNF24 is linked to cancer.